National Institutes of Health: Mesothelioma trials

The registry lists 48 Mesothelioma studies with National Institutes of Health as lead sponsor. 6 are open to participants now and 19 have results posted.

Early Phase 1 1Phase 1 21Phase 2 24No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingNCT06885697Phase 1
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
• Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaRecruitingNCT05960773Phase 2
• Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition SyndromeRecruitingNCT04431024
• Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1RecruitingNCT03830229
• Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT01950572
• Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaTerminatedNCT04840615Phase 1Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsCompletedNCT04034238Phase 1Results posted
• Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaTerminatedNCT03644550Phase 2Results posted
• Olaparib in People With Malignant MesotheliomaCompletedNCT03531840Phase 2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaTerminatedNCT03436732Phase 1Results posted
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesTerminatedNCT02859415Phase 1/2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant MesotheliomaCompletedNCT02798536Phase 1Results posted
• Tivantinib in Treating Patients With Previously Treated Malignant MesotheliomaTerminatedNCT01861301Phase 2Results posted
• Mithramycin for Lung, Esophagus, and Other Chest CancersTerminatedNCT01624090Phase 2Results posted
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic CancerTerminatedNCT01583686Phase 1/2Results posted
• SS1P and Pentostatin Plus Cyclophosphamide for MesotheliomaCompletedNCT01362790Phase 1/2Results posted
• Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With ChemotherapyCompletedNCT01160458Phase 2Results posted
• Pazopanib in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00459862Phase 2Results posted
• Sunitinib in Treating Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT00392444Phase 2Results posted
• PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By SurgeryCompletedNCT00365053Phase 2Results posted
• Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00309946Phase 2Results posted
• S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00243074Phase 2Results posted
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and ChemotherapyCompletedNCT00004547Phase 2Results posted
• Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage MesotheliomaWithdrawnNCT06654050Phase 2
• Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing MesothelinWithdrawnNCT05375825Phase 1
• Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical TrialsCompletedNCT02948413
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Rapid Autopsy and Procurement of Cancer TissueTerminatedNCT01851395
• SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural MesotheliomaTerminatedNCT01445392Phase 1
• Amatuximab for High Mesothelin CancersTerminatedNCT01413451Early Phase 1
• Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural MesotheliomasTerminatedNCT01258868Phase 1
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1
• AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural MesotheliomaWithdrawnNCT01105390Phase 2
• Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.CompletedNCT00107432Phase 2
• Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedNCT00094978Phase 1
• Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
• Erlotinib in Treating Patients With Malignant Mesothelioma of the LungCompletedNCT00039182Phase 2
• Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural MalignanciesCompletedNCT00037817Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural CancerTerminatedNCT00028782Not applicable
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant MesotheliomaCompletedNCT00027703Phase 2
• Gefitinib in Treating Patients With Malignant MesotheliomaCompletedNCT00025207Phase 2
• Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the LungsCompletedNCT00020124Phase 1
• Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the PleuraCompletedNCT00019825Phase 1
• Immunotoxin Therapy in Treating Patients With Advanced CancerCompletedNCT00006981Phase 1
• SU5416 in Treating Patients With Malignant MesotheliomaCompletedNCT00006014Phase 2